Business development: Secures royalty economic interests in two early stage partnered assets through XOMA Royalty's announced expected acquisition of LAVA Therapeutics.
Company acquisitions: --Completed XOMA Royalty's acquisitions of Turnstone Biologics and HilleVax; -- announced acquisitions of LAVA Therapeutics and Mural Oncology; -- acted as structuring agent for XenoTherapeutics' acquisition of ESSA Pharma.
Key Pipeline advancements: -- Zevra Therapeutics submitted a Marketing Authorization Application $(MAA)$ with the European Medicines Agency $(EMA)$ seeking marketing approval for arimoclomol as a treatment for Niemann-Pick Type C; -- Rezolute Bio reconfirmed its expectations to announce topline data in December from its Phase 3 ersodetug trial in patients with congenital hyperinsulinism $(HI)$ and announced alignment with FDA on streamlined design for ongoing Phase 3 trial of ersodetug in tumor HI; --Gossamer Bio expects topline results from PROSERA, its Phase 3 trial of seralutunib in pulmonary atrial hypertension (PAH), in February 2026.
Cash receipts: In the first nine months of 2025, XOMA Royalty received $43.9 million in royalties and milestones from its partners, including $14.3 million from royalties during the third quarter.
EMERYVILLE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation $(XOMA)$, the biotech royalty aggregator, reported its 2025 third quarter and year to date financial results and highlighted recent actions that have the potential to deliver additional shareholder value.
"We continue to execute on innovative ways to increase optionality within our portfolio while maintaining a healthy cash balance and limiting dilution to our shareholders," stated Owen Hughes, Chief Executive Officer of XOMA Royalty. "Growing royalty receipts reflect solid commercial execution on the part of our partners. We look forward to several clinical readouts over the coming months and quarters that, if positive, can meaningfully shape our business trajectory."
Royalty and Milestone Acquisitions
Company Asset and Transaction Detail
----------------- -----------------------------------------------------------
LAVA Therapeutics XOMA Royalty will secure an economic interest in
PF-08046052, which is being developed by Pfizer, and
JNJ-89853413, which is being developed by Johnson &
Johnson, upon closing its acquisition of LAVA.
Company Acquisitions
Company Transaction Details
-------------------------------------- --------------------------------------
Turnstone Biologics XOMA Royalty acquired Turnstone for
$0.34 in cash per share of Turnstone
common stock plus one non-transferable
contingent value right $(CVR)$.
HilleVax XOMA Royalty acquired HilleVax for a
cash payment of $1.95 per share plus a
non-transferable CVR that entitles
holders to receive certain potential
payments.
LAVA Therapeutics XOMA Royalty will acquire LAVA for (i)
an initial cash amount per share of
$1.04 plus (ii) a non-transferable CVR
per share representing the right to
receive certain cash payments,
including $(A)$ the previously announced
rights to receive, among other things,
75% of the net proceeds related to
LAVA's two partnered assets plus 75%
of any net proceeds from any out
license or sale of LAVA's unpartnered
programs, plus $(B)$ a new right to
receive up to approximately $0.23 per
CVR depending on the final
determination after closing of certain
potential liabilities.
Mural Oncology XOMA Royalty will acquire Mural
Oncology through its wholly owned
subsidiary XRA 5 Corp. for between
$2.035 and $2.24 in cash per share.
The acquisition is expected to close
in the fourth quarter of 2025.(1) (,)
(2)
XenoTherapeutics Acquisition of ESSA XOMA Royalty acted as structuring
Pharma agent for XenoTherapeutics' completed
acquisition of ESSA Pharma.
Pipeline Partner Updates through November 10, 2025
Partner Event
--------------------- -------------------------------------------------------
Rezolute In September, Rezolute announced it had achieved
alignment with FDA on a significantly streamlined
clinical development path for its ongoing Phase 3 study
(upLIFT) of ersodetug for the treatment of tumor HI.
Topline results are expected in the second half of
2026.(3)
Takeda The first patient was dosed in Takeda's Phase 3
clinical trial investigating mezagitamab as a treatment
for adults with IgA Nephropathy.
Zevra Therapeutics On July 28, Zevra announced it had submitted an MAA to
EMA for the evaluation of arimoclomol for the treatment
of Niemann-Pick Disease Type C (NPC)(4) .
Gossamer Bio Activated first clinical site for the global,
registrational Phase 3 SERANATA study examining
seralutinib in patients with pulmonary hypertension
associated with interstitial lung disease (PH-ILD) in
the fourth quarter of 2025(5) .
Daré Biosciences Announced positive interim safety and efficacy results
from its ongoing Phase 3 clinical trial evaluating the
contraceptive effectiveness, safety, and acceptability
of Ovaprene$(R)$, an investigational monthly,
hormone-free intravaginal contraceptive.(6)
Anticipated Partner Events of Note through Mid-2026
Partner Event
-------------------------- --------------------------------------------------
Rezolute Announces topline data in December 2025(7) from
sunRIZE Phase 3 clinical trial, which is
investigating ersodetug in infants and children
with congenital HI.
Gossamer Bio Publishes topline results from the Phase 3 PROSERA
Study evaluating seralutinib in Functional Class
II and III PAH patients(5) .
Daré Bioscience Makes DARE to PLAY$(TM)$ Sildenafil Cream available
commercially via prescription in the fourth
quarter of 2025 as a compounded drug under Section
503B of the Federal Food, Drug, and Cosmetic
Act.(8) Commences one of two registrational Phase
3 clinical trials investigating Sildenafil Cream,
3.6%, for the treatment of female sexual arousal
disorder(9) . Discussions with FDA regarding
endpoint assessment for Phase 3 clinical studies
of Sildenafil Cream, 3.6% continue(8) .
Day One Biopharmaceuticals Per the Day One conference call held on November
4, 2025, Ipsen, Day One's partner outside the
U.S., expects to receive EMA regulatory decision
on its application to commercialize tovorafenib in
the European Union.
(1) https://investors.xoma.com/news-events/press-releases/detail/482/mural-oncology-announces-entry-into-agreement-to-be
(2) http://ml.globenewswire.com/Resource/Download/538d82a8-0fae-4d41-8687-71845b9b67c2
(3) https://ir.rezolutebio.com/news/detail/361/rezolute-announces-alignment-with-fda-on-streamlined-design-for-ongoing-phase-3-trial-of-ersodetug-in-tumor-hyperinsulinism
(4) https://investors.zevra.com/news-releases/news-release-details/zevra-therapeutics-submits-marketing-authorization-application
(5) https://ir.gossamerbio.com/news-releases/news-release-details/gossamer-bio-announces-third-quarter-2025-financial-results-and
(6) https://ir.darebioscience.com/news-releases/news-release-details/positive-interim-phase-3-results-highlight-potential-ovaprener
(7) https://ir.rezolutebio.com/news/detail/366/rezolute-reports-first-quarter-fiscal-2026-financial-results-and-provides-business-update
(8) https://ir.darebioscience.com/news-releases/news-release-details/dare-bioscience-reports-second-quarter-2025-financial-results
(9) https://ir.darebioscience.com/news-releases/news-release-details/dare-bioscience-announces-phase-3-plans-sildenafil-cream-36
Third Quarter and Year to Date 2025 Financial Results
Tom Burns, Chief Financial Officer of XOMA Royalty, commented, "In the first nine months of 2025, we have received $43.9 million in cash from partners, of which $30.3 million were royalty payments related to commercial sales and $13.6 million in milestone payments and fees. In the third quarter, we received $14.3 million in cash from our partners' commercial sales. With well-executed commercialization efforts by our partners and the emergence of new commercial opportunities from within our portfolio, XOMA Royalty has the potential to become a self-sustaining entity from royalties alone over the near term."
Income and Revenue: Income and revenue for the three and nine months ended September 30, 2025, were $9.4 million and $38.4 million, respectively, as compared with $7.2 million and $19.8 million for the corresponding periods of 2024. The increase in both periods presented was primarily driven by increased income related to VABYSMO and OJEMDA.
Research and Development (R&D) Expenses: R&D expenses for the three and nine months ended September 30, 2025, were $69 thousand and $1.4 million, respectively, compared with $0.8 million and $2.0 million for each of the corresponding periods of 2024. R&D expenses in the first quarter of 2025 and the three- and nine-month periods of 2024 were related to the clinical trial costs incurred subsequent to XOMA Royalty's acquisition of Kinnate in April 2024 related to KIN-3248 and the associated wind-down activities.
General and Administrative (G&A) Expenses: G&A expenses for the three and nine months ended September 30, 2025, were $9.7 million and $25.7 million, respectively, as compared with $8.0 million and $27.5 million for the corresponding periods of 2024. The increase of $1.7 million for the three months ended September 30, 2025, as compared to the same period in 2024, was primarily due to an increase in business development and deal-related costs, partially offset by a decrease in stock-based compensation expense. For the nine months ended September 30, 2025, the decrease of $1.8 million, as compared to the same period in 2024, was primarily due to costs related to exit packages for Kinnate senior leadership in the second quarter of 2024 and a decrease in stock-based compensation expense, partially offset by an increase in business development and deal-related costs.
XOMA Royalty's G&A expenses included non-cash stock-based compensation expenses during the three and nine months ended September 30, 2025, of $1.8 million and $5.4 million, respectively, as compared to $2.6 million and $8.1 million for the corresponding periods of 2024. The 2024 periods reflect non-cash stock-based compensation related to the appointment of Mr. Hughes to full-time Chief Executive Officer and issuance of performance stock units.
Credit Losses on Purchased Receivables: During the nine months ended September 30, 2024, XOMA Royalty recorded one-time, non-cash credit losses on purchased receivables associated with the Aronora and Agenus assets. To date, there have been no credit losses in 2025.
Amortization of Intangible Assets: Amortization of intangible assets relates to the IP acquired in the Company's acquisitions of Pulmokine in November 2024 and the mezagitamab economics from the BioInvent transaction in May 2025. Amortization of non-cash intangible assets were $0.9 million and $2.1 million for the three and nine months ended September 30, 2025.
Gains on Acquisitions: In the third quarter of 2025, XOMA Royalty recorded gains on acquisitions of $17.9 million for HilleVax and $1.8 million for Turnstone.
Interest Expense: For the three and nine months ended September 30, 2025, interest expense was $3.3 million and $10.0 million, respectively, as compared with $3.5 million and $10.4 million for the corresponding periods of 2024. Interest expense relates to the Blue Owl Loan established in December 2023.
Other Income, net: For the three and nine months ended September 30, 2025, other income, net was $0.7 million and $8.5 million, respectively, as compared with $1.9 million and $5.9 million for the corresponding periods of 2024.
Net Income: XOMA Royalty reported net income of $14.1 million and $25.6 million for the three and nine months ended September 30, 2025, as compared to net losses of $17.2 million and $9.9 million in the corresponding periods of 2024.
Cash Position: On September 30, 2025, XOMA Royalty had cash and cash equivalents of $130.6 million, including $85.4 million in restricted cash. The restricted cash balance included $43.3 million related to the assumed HilleVax lease, $39.9 million reserved to fund the Mural acquisition, and $2.2 million related to the Blue Owl Loan. Cash and cash equivalents of $106.4 million as of December 31, 2024, included $4.8 million in restricted cash related to the Blue Owl Loan.
In the third quarter of 2025, XOMA Royalty received $14.3 million in cash receipts from royalties and commercial payments and paid $1.4 million in dividends on the XOMA Royalty Perpetual Preferred stocks. In the first nine months of 2025, XOMA Royalty received $43.9 million in cash receipts, including $30.3 million in royalties and commercial payments and $13.6 million in milestone payments and fees. During the first nine months of 2025, XOMA Royalty deployed $25.0 million to acquire additional assets for its royalty and milestone portfolio, repurchased approximately 108,510 shares of its common stock for a cost of $2.4 million, and paid $4.1 million in dividends on the XOMA Royalty Perpetual Preferred stocks.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.
Forward-Looking Statements/Explanatory Notes
Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential commercial payments to XOMA Royalty and other developments related to VABYSMO(R) (faricimab-svoa), OJEMDA(TM) (tovorafenib), MIPLYFFA(TM) (arimoclomol), XACIATO(TM) (clindamycin phosphate) vaginal gel 2%, IXINITY(R) [coagulation factor IX (recombinant)], DSUVIA(R) (sufentanil sublingual tablet), and Sildenafil Cream, 3.6%; the potential occurrences of the events listed under "Anticipated 2025 Events of Note"; the anticipated timings of regulatory filings and approvals related to assets in XOMA Royalty's portfolio; and the potential of XOMA Royalty's portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project, " "expect," "may," "will", "would," "could" or "should," the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA Royalty's performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; and if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them. Other potential risks to XOMA Royalty meeting these expectations are described in more detail in XOMA Royalty's most recent filing on Form 10-Q and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA Royalty's prospects. Any forward-looking statement in this press release represents XOMA Royalty's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA Royalty disclaims any obligation to update any forward-looking statement, except as required by applicable law.
EXPLANATORY NOTE: Any references to "portfolio" in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to "assets" in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.
As of the date of this press release, the commercial assets in XOMA Royalty's milestone and royalty portfolio are VABYSMO(R) (faricimab-svoa), OJEMDA(TM) (tovorafenib), MIPLYFFA(TM) (arimoclomol), XACIATO(TM) (clindamycin phosphate) vaginal gel 2%, IXINITY(R) [coagulation factor IX (recombinant)], and DSUVIA(R) (sufentanil sublingual tablet). All other assets in the milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available.
XOMA ROYALTY CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except share and per share amounts)
Three Months Ended Nine Month Ended
September 30, September 30,
------------------- --------------------
2025 2024 2025 2024
Income and
Revenues:
Income from
purchased
receivables
under the EIR
method $ 6,962 $ 5,423 $ 19,039 $ 9,985
Income from
purchased
receivables
under the cost
recovery method 1,857 1,040 9,125 1,910
Revenue from
contracts with
customers 225 25 9,250 6,050
Revenue
recognized under
units-of-revenue
method 307 709 978 1,828
Total income
and revenues 9,351 7,197 38,392 19,773
------ ------- ------- -------
Operating expenses:
Research and
development 69 817 1,431 2,011
General and
administrative 9,734 8,020 25,682 27,485
Credit losses on
purchased
receivables - 14,000 - 23,000
Amortization of
intangible
assets 878 - 2,077 -
Total operating
expenses 10,681 22,837 29,190 52,496
------ ------- ------- -------
Income (Loss)
from
operations (1,330) (15,640) 9,202 (32,723)
Other income
(expense)
Gains on
acquisitions 18,004 - 18,004 19,316
Change in fair
value of
embedded
derivative
related to RPA - - - 8,100
Interest expense (3,301) (3,493) (10,004) (10,446)
Other income, net 727 1,890 8,456 5,900
------ ------- ------- -------
Net income $14,100 $(17,243) $ 25,658 $ (9,853)
Income tax expense $ (49) $ - $ (49) $ -
Net income (loss) $14,051 $(17,243) $ 25,609 $ (9,853)
====== ======= ======= =======
Net income (loss)
available to
(attributable to)
common
stockholders,
basic $ 8,981 $(18,611) $ 15,192 $(13,957)
====== ======= ======= =======
Basic net income
per share
available to
common
stockholders $ 0.74 $ (1.59) $ 1.26 $ (1.20)
====== ======= ======= =======
Weighted average
shares used in
computing basic
net income per
share available to
common
stockholders 12,137 11,712 12,038 11,645
====== ======= ======= =======
Net income (loss)
available to
(attributable to)
common
stockholders,
diluted $12,683 $(18,611) $ 21,505 $(13,957)
====== ======= ======= =======
Diluted net income
per share
available to
common
stockholders $ 0.70 $ (1.59) $ 1.20 $ (1.20)
====== ======= ======= =======
Weighted average
shares used in
computing diluted
net income per
share available to
common
stockholders 18,141 11,712 17,932 11,645
====== ======= ======= =======
XOMA ROYALTY CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in thousands, except share and per share amounts)
September 30, December 31,
2025 2024
ASSETS
Current assets:
Cash and cash equivalents $ 45,189 $ 101,654
Short-term restricted cash 45,288 1,330
Investment in equity securities 1,521 3,529
Trade and other receivables, net 3,573 1,839
Short-term royalty and commercial
payment receivables under the
EIR method 13,269 14,763
Short-term royalty and commercial
payment receivables under the
cost recovery method 900 413
Prepaid expenses and other
current assets 967 2,076
---------- ----------
Total current assets 110,707 125,604
Long-term restricted cash 40,076 3,432
Property and equipment, net 24 32
Operating lease right-of-use
assets 272 319
Long-term royalty and commercial
payment receivables under the
EIR method 4,678 4,970
Long-term royalty and commercial
payment receivables under the
cost recovery method 57,864 55,936
Exarafenib milestone asset 3,500 3,214
Investment in warrants 595 -
Intangible assets, net 44,556 25,909
Other assets - long term 879 1,861
Total assets $ 263,151 $ 221,277
========== ==========
LIABILITIES, CONVERTIBLE PREFERRED
STOCK AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 2,654 $ 1,053
Accrued and other liabilities 4,134 5,752
Contingent consideration under
RPAs, AAAs, and CPPAs - 3,000
Operating lease liabilities 2,508 446
Unearned revenue recognized under
units-of-revenue method 1,320 1,361
Preferred stock dividend accrual 1,368 1,368
Current portion of long-term debt 14,345 11,394
Contingent value rights
liabilities - current portion 1,976 -
Total current liabilities 28,305 24,374
Unearned revenue recognized under
units-of-revenue method --
long-term 3,473 4,410
Exarafenib milestone contingent
consideration 3,500 3,214
Long-term operating lease
liabilities 20,678 483
Long-term debt 94,382 106,875
Contingent value rights
liabilities - long-term 4,807 -
Deferred tax liability 49 -
Total liabilities 155,194 139,356
---------- ----------
Convertible preferred stock, $0.05
par value, 5,003 shares
authorized, issued and outstanding
as of September 30, 2025 and
December 31, 2024 20,019 20,019
Stockholders' equity:
8.625% Series A cumulative,
perpetual preferred stock, $0.05
par value, 984,000 shares
authorized, issued and
outstanding as of September 30,
2025 and December 31, 2024 49 49
8.375% Series B cumulative,
perpetual preferred stock, $0.05
par value, 3,600 shares
authorized, 1,600 shares issued
and outstanding as of September
30, 2025 and December 31, 2024 -- --
Common stock, $0.0075 par value,
277,333,332 shares authorized,
12,310,300 and 11,952,377 shares
issued and outstanding as of
September 30, 2025 and December
31, 2024, respectively 92 90
Additional paid-in capital 1,301,542 1,298,747
Accumulated other comprehensive
income 121 73
Accumulated deficit (1,213,866) (1,237,057)
---------- ----------
Total stockholders' equity 87,938 61,902
---------- ----------
Total liabilities,
convertible preferred stock
and stockholders' equity $ 263,151 $ 221,277
========== ==========
XOMA ROYALTY CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands)
Nine Months Ended September 30,
2025 2024
Cash flows from operating
activities:
Net income $ 25,609 $ (9,853)
Adjustments to reconcile net
income to net cash provided by
(used in) operating
activities:
Adjustment for income from
EIR method purchased
receivables 627 (9,985)
Stock-based compensation
expense 5,358 8,136
Gains on acquisitions (18,004) (19,316)
Credit losses on purchased
receivables -- 23,000
Gain on sale of equity
securities (3,663) --
Income tax expense 49 --
Common stock contribution to
401(k) 141 118
Amortization of intangible
assets 2,077 --
Depreciation 8 8
Accretion of long-term debt
discount and debt issuance
costs 1,136 996
Non-cash lease expense 47 45
Change in fair value of
equity securities (1,230) (624)
Change in fair value of
available-for-sale debt
securities classified as
cash equivalents 49 104
Change in fair value of
derivatives 10 --
Changes in assets and
liabilities:
Trade and other receivables,
net (1,187) (41)
Prepaid expenses and other
assets 1,839 (72)
Accounts payable and accrued
liabilities (3,248) (1,348)
Operating lease liabilities (268) (185)
Unearned revenue recognized
under units-of-revenue
method (978) (1,828)
------------- ------------
Net cash provided by (used
in) operating activities 8,372 (10,845)
------------- ------------
Cash flows from investing
activities:
Net cash acquired in Kinnate
acquisition -- 18,926
Net cash, cash equivalents and
restricted cash acquired in
Turnstone acquisition 3,943 --
Net cash, cash equivalents and
restricted cash acquired in
HilleVax acquisition 46,832 --
Payments of consideration under
RPAs, AAAs, and CPPAs (8,000) (37,000)
Receipts under RPAs, AAAs, and
CPPAs 3,139 26,263
Payment for BioInvent
contract-based intangible
asset (20,725) --
Payment of contingent
consideration related to
Kinnate IP asset (550) --
Purchase of property and
equipment -- (17)
Purchase of equity securities (99) --
Sale of equity securities 6,999 --
Net cash used in investing
activities 31,539 8,172
------------- ------------
Cash flows from financing
activities:
Principal payments -- debt (10,598) (6,902)
Debt issuance costs and loan
fees paid in connection with
long-term debt (80) (740)
Payment of preferred stock
dividends (4,104) (4,104)
Repurchases of common stock (2,395) (13)
Proceeds from exercise of
options and other share-based
compensation 3,422 4,127
Taxes paid related to net share
settlement of equity awards (2,019) (2,429)
Net cash used in financing
activities (15,774) (10,061)
------------- ------------
Net increase (decrease) in cash,
cash equivalents, and restricted
cash 24,137 (12,734)
Cash, cash equivalents, and
restricted cash at the beginning
of the period 106,416 159,550
Cash, cash equivalents, and
restricted cash at the end of
the period $ 130,553 $ 146,816
============= ============
Supplemental Cash Flow
Information:
Cash paid for interest $ 11,906 $ 9,985
Cash paid for taxes $ 277 $ --
Non-cash investing and financing
activities:
Accrual of contingent value
rights liability in the
Turnstone acquisition $ 1,110 $ --
Accrual of contingent value
rights liability in the
HilleVax acquisition $ 5,673 $ --
Right-of-use assets obtained in
exchange for operating lease
liabilities in the HilleVax
acquisition $ 22,525 $ --
Relative fair value basis
reduction of right-of-use
assets in the HilleVax
acquisition $ (22,525) $ --
Transaction costs in connection
with the Turnstone acquisition
included in accounts payable $ 92 $ --
Transaction costs in connection
with the HilleVax acquisition
included in accounts payable
and accrued expenses $ 449 $ --
Excise tax accrual due to stock
repurchases $ 24 $ --
Preferred stock dividend
accrual $ 1,368 $ 1,368
Estimated fair value of the
Exarafenib milestone asset $ -- $ 2,922
Estimated fair value of the
Exarafenib milestone
contingent consideration $ -- $ 2,922
Right-of-use assets obtained in
exchange for operating lease
liabilities in the Kinnate
acquisition $ -- $ 824
Relative fair value basis
reduction of rights-of-use
assets in the Kinnate
acquisition $ -- $ (824)
Accrual of contingent
consideration under the
Affitech CPPA $ -- $ 3,000
Accrual of contingent
consideration under the LadRX
AAA $ -- $ 1,000
Investor contact: Media contact:
Juliane Snowden Kathy Vincent
XOMA Royalty Corporation KV Consulting & Management
+1-646-438-9754 kathy@kathyvincent.com
juliane.snowden@xoma.com
(END) Dow Jones Newswires
November 12, 2025 07:30 ET (12:30 GMT)
Comments